IASLC Global Survey on Biomarker Testing in Lung Cancer – 2024 Update | IASLC
Biomarker testing is essential in lung cancer care, allowing for personalized diagnosis and treatment. Survey closes March 23, 2024.
Biomarker testing is essential in lung cancer care, allowing for personalized diagnosis and treatment. Survey closes March 23, 2024.
In his closing remarks, Yi-Bin Chen, MD, shares his aspirations for the future of graft versus host disease management, emphasizing the need for further clinical…
High-intensity focused ultrasound produced noninferior salvage treatment-free survival vs radical prostatectomy in localized prostate cancer.
Cretostimogene grenadenorepvec elicited durable responses in high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.
Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE…
The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.
GeekWire co-founders Todd Bishop, left, and John Cook open the 2024 GeekWire Awards at Showbox SoDo in Seattle on Thursday. (GeekWire Photo / Kevin
Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses the diagnosis and prognosis of patients with locally advanced cutaneous squamous cell carcinoma.
Event in Whiteville, TN by Elizabeth Young on Friday, June 7 2024
Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.
Medical experts discuss the selection of second-line treatments for patients who experience disease progression while on first-line therapy, highlighting the potential for deterioration in performance…